Search research articles
Contact Us
Filters
Showing results (211-220 of 265) with videos related to
Page
of 27
Sort By:
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
Ivelina Spassova, Selma Ugurel, Linda Kubat, et al.
International Journal of Cancer
|
July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
Sebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma
Georg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Frontiers of Medicine
|
July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
Cancers
|
June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study
Henner Stege, Maximilian Haist, Michael Schultheis, et al.
Page
of 27
Search research articles
Search
Showing results (211-220 of 265) with videos related to
Sort By:
Page
of 27
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
Ivelina Spassova, Selma Ugurel, Linda Kubat, et al.
International Journal of Cancer
|
July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
Sebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma
Georg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Frontiers of Medicine
|
July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
Cancers
|
June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study
Henner Stege, Maximilian Haist, Michael Schultheis, et al.
Page
of 27